Filtered By:
Management: Medicare
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 992 results found since Jan 2013.
Oh, You Have Medicare? We'll Skip That Test.
(MedPage Today) -- *Patient's name has been changed
Magda* was 70 years old when she suffered a mild stroke. She was taken to a hospital, where the emergency department and critical care unit ran the appropriate tests and sent her home with medicine...
Source: MedPage Today Public Health - June 8, 2023 Category: American Health Source Type: news
Medicare Patients with Symptomatic Carotid Disease Requiring Carotid Revascularization Are Likely to Have Delayed Access: An Analysis of a Multicenter Surgical Data
The Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease recommends carotid revascularization as soon as the patient is neurologically stable after 48 hours and before 14 days of symptom onset in patients with recent stroke. In the United States, insurance status has been demonstrated to play a role in wait times for surgical care. There are no large-scale studies that assess the effect of patient primary insurance status on time to surgery in patients with symptomatic carotid disease.
Source: Journal of Vascular Surgery - May 23, 2023 Category: Surgery Authors: Daniel Willie-Permor, Gabriela Sendek, Marjan Moghaddam, Sina Zarrintan, Mahmoud Malas Tags: Poster Competition Source Type: research
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study
CONCLUSION: In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol.PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.PMID:37216662 | DOI:10.7326/M22-3238
Source: Annals of Internal Medicine - May 22, 2023 Category: Internal Medicine Authors: Wayne A Ray Cecilia P Chung C Michael Stein Walter Smalley Eli Zimmerman William D Dupont Adriana M Hung James R Daugherty Alyson L Dickson Katherine T Murray Source Type: research
Shorter Door-to-Needle Times Are Associated With Better Outcomes After Intravenous Thrombolytic Therapy and Endovascular Thrombectomy for Acute Ischemic Stroke
CONCLUSIONS: Among older patients with stroke treated with either IVT only or IVT+EVT, shorter DTN times are associated with better long-term functional outcomes and lower mortality. These findings support further efforts to accelerate thrombolytic administration in all eligible patients, including EVT candidates.PMID:37199147 | DOI:10.1161/CIRCULATIONAHA.123.064053
Source: Circulation - May 18, 2023 Category: Cardiology Authors: Shumei Man Nicole Solomon Brian Mac Grory Brooke Alhanti Ken Uchino Jeffrey L Saver Eric E Smith Ying Xian Deepak L Bhatt Lee H Schwamm Muhammad Shazam Hussain Gregg C Fonarow Source Type: research
Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research
Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial
CONCLUSIONS: For patients with severe aortic stenosis and low surgical risk similar to those enrolled in the PARTNER 3 trial, transfemoral TAVR with the SAPIEN 3 valve is cost saving compared with SAVR at 2 years and is projected to be economically attractive in the long run as long as there are no substantial differences in late death between the 2 strategies. Long-term follow-up will be critical to ultimately determine the preferred treatment strategy for low-risk patients from both a clinical and economic perspective.PMID:37154049 | DOI:10.1161/CIRCULATIONAHA.122.062481
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Benjamin Z Galper Khaja M Chinnakondepalli Kaijun Wang Elizabeth A Magnuson Michael Lu Vinod H Thourani Susheel Kodali Raj Makkar Howard C Herrmann Samir Kapadia Mathew Williams John Webb Craig R Smith Michael J Mack Martin B Leon David J Cohen PARTNER In Source Type: research
Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research
Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial
CONCLUSIONS: For patients with severe aortic stenosis and low surgical risk similar to those enrolled in the PARTNER 3 trial, transfemoral TAVR with the SAPIEN 3 valve is cost saving compared with SAVR at 2 years and is projected to be economically attractive in the long run as long as there are no substantial differences in late death between the 2 strategies. Long-term follow-up will be critical to ultimately determine the preferred treatment strategy for low-risk patients from both a clinical and economic perspective.PMID:37154049 | DOI:10.1161/CIRCULATIONAHA.122.062481
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Benjamin Z Galper Khaja M Chinnakondepalli Kaijun Wang Elizabeth A Magnuson Michael Lu Vinod H Thourani Susheel Kodali Raj Makkar Howard C Herrmann Samir Kapadia Mathew Williams John Webb Craig R Smith Michael J Mack Martin B Leon David J Cohen PARTNER In Source Type: research
